ESMO Open最新文献

{"title":"88P A comparative survival in male breast cancer subtypes by race/ethnicity","authors":"W. Dwairi , M. Alhamad","doi":"10.1016/j.esmoop.2025.104642","DOIUrl":"10.1016/j.esmoop.2025.104642","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104642"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"31P Enhanced NGS-based PTEN testing comprehensively identifies PTEN structural variants in breast cancer","authors":"A.C. Tuck , F. Mohammad , X. Li , A. Yarunin , X. Xing , C. Pozzorini , B. Foth , T. Coletta , X. Peng , D. Ivanov , A. Willig , L. Song , J.W. Longshore , Z. Xu","doi":"10.1016/j.esmoop.2025.104585","DOIUrl":"10.1016/j.esmoop.2025.104585","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104585"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144068066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"12P Real-world experience of longitudinal circulating tumor (ct)DNA monitoring in patients (pts) with early-stage triple-negative breast cancer (TNBC)","authors":"M.L. Telli , S. Rivero-Hinojosa , S. Satta , S.L. Bristow , M. Malhotra , E. Kalashnikova , A.A. Rodriguez , M.C. Liu , L. Pusztai","doi":"10.1016/j.esmoop.2025.104566","DOIUrl":"10.1016/j.esmoop.2025.104566","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104566"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144068210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"94P ML-based pathological and radiological features reveal deeper insights into histological response to neoadjuvant therapies in HER2-positive early breast cancer","authors":"V. Debien , A-E. Mrani , R.F. Salgado , K. Abduljabbar , P. Kristanto , M. Ignatiadis , C. Sotiriou , E. de Azambuja , S. Drisis","doi":"10.1016/j.esmoop.2025.104648","DOIUrl":"10.1016/j.esmoop.2025.104648","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104648"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144068411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"89P Impact of differentially expressed coding RNAs on adjuvant chemotherapy efficacy in vimentin-positive breast cancer patients","authors":"Y. Ichinose , A. Osaki , M. Miyazaki , T. Kurosawa , A. Nakame , A. Sakakibara , A. Fujimoto , A. Nukui , A. Asano , H. Shimada , H. Yokogawa , M. Ohara , K. Matsuura , T. Hasebe , H. Ishiguro , T. Takahashi , T.N. Saeki","doi":"10.1016/j.esmoop.2025.104643","DOIUrl":"10.1016/j.esmoop.2025.104643","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104643"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"22P Central reassessment of HER2 status in HER2-positive tumors identified as ERBB2-low by the HER2DX genomic test","authors":"O. Martinez Saez , M. Marin , J.M. Cejalvo , M. Tapia Céspedes , B. Bermejo , A. Santaballa Bertran , V. Sirenko , Á. Aguirre , A. Llombart Cussac , E. Hernández-Illán , P. Jares , L. Pare Brunet , W. Buckingham , J. Parker , P. Villagrasa Gonzalez , T. Pascual , M.J. Vidal Losada , M. Munoz , A. Prat , E. Sanfeliu Torres","doi":"10.1016/j.esmoop.2025.104576","DOIUrl":"10.1016/j.esmoop.2025.104576","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104576"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144067972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1O Kinetics and determinants of blood ESR1 mutation under AI and palbociclib in HR+/HER2- metastatic breast cancer patients in the PADA-1 trial","authors":"L. Cabel , T. Bachelot , A-C. Hardy-Bessard , B. Pistilli , F. Dalenc , T. De La Motte Rouge , C. Callens , R. Sabatier , J-S. Frenel , S. Ladoire , J. Grenier , L. Stefani , H. Vegas , I. Bieche , S. Delaloge , A. Pradines , J. Lemonnier , F. Berger , F.C. Bidard","doi":"10.1016/j.esmoop.2025.104556","DOIUrl":"10.1016/j.esmoop.2025.104556","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104556"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144068398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance and considerations in the use of diagnostic mutation panels for clonality testing in non-small-cell lung carcinoma","authors":"J. Janssen ,&nbsp;B. Andrade Barbosa ,&nbsp;J.C. Machado ,&nbsp;P. Hofman ,&nbsp;Y. Kim ,&nbsp;B. Ylstra ,&nbsp;T. Radonic","doi":"10.1016/j.esmoop.2025.105072","DOIUrl":"10.1016/j.esmoop.2025.105072","url":null,"abstract":"<div><h3>Introduction</h3><div>Next-generation sequencing (NGS) mutation panels are widely implemented and commonly applied to aid clonality classification for non-small-cell lung carcinoma (NSCLC) patients with multiple tumors. Performance of different NGS panels for clonality classification, however, remains unresolved.</div></div><div><h3>Methods</h3><div>We assembled 210 primary and metastatic pairs from lung adenocarcinoma (LUAD) and lung squamous-cell carcinomas (LUSC) of the TRACERx421 cohort for which gold standard clonality was confirmed by whole exome sequencing. We used four NGS panels ranging from 12 to 523 genes to determine clonality using the 2024 International Association for the Study of Lung Cancer (IASLC) recommendations.</div></div><div><h3>Results</h3><div>With an oncogene panel, 30% LUAD and 74% LUSC pairs remained inconclusive with, respectively, 2% and 0% misclassified. Addition of tumor suppressor genes results in 5% LUAD and 5% LUSC inconclusive and, respectively, 2% and 1% misclassified. For large panels, 0%-1% was inconclusive and 1% misclassified for both LUAD and LUSC. Misclassifications occurred due to discordant <em>KRAS</em> mutations in clonal pairs or coincidentally shared <em>PIK3CA</em> mutations in non-clonal pairs.</div></div><div><h3>Conclusion</h3><div>Oncogene panels result in many inconclusive results, most of which can be resolved by adding tumor suppressor genes. Notwithstanding, 1%-2% of patients remain challenging. Large NGS panels detect mutations in more genes than the IASLC recommendations, allowing definitive clonality classification.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 5","pages":"Article 105072"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143943578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of whole genome sequencing on the care pathway for patients with cancer of unknown primary","authors":"E. Droogers ,&nbsp;Y. Teunissen ,&nbsp;A.J. van Puffelen ,&nbsp;F.H. Groenendijk ,&nbsp;S.E.M. Veldhuijzen van Zanten ,&nbsp;A. Wagner ,&nbsp;H.M.W. Verheul ,&nbsp;D.G.J. Robbrecht","doi":"10.1016/j.esmoop.2025.105069","DOIUrl":"10.1016/j.esmoop.2025.105069","url":null,"abstract":"<div><h3>Background</h3><div>Patients with metastatic disease and no identifiable primary tumor, thus diagnosed with cancer of unknown primary (CUP), typically have a poor prognosis. Tumor DNA sequencing has recently shown promise in identifying the molecular tissue of origin. This study evaluated the value of whole genome sequencing (WGS) in the CUP care pathway, by comparing patient outcomes with a historical control cohort. Also, the value of whole transcriptome sequencing (WTS) was explored.</div></div><div><h3>Patients and methods</h3><div>A prospective intervention cohort was established of provisional CUP patients (≥18 years of age) who had WGS carried out on metastatic tissue between August 2021 and August 2023. A control cohort was established of CUP patients (≥18 years of age) diagnosed between December 2016 and April 2021 without the availability of WGS. The CUP predicting algorithm was applied to WGS data, and data on definitive diagnosis, molecular actionable alterations [ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) tier 1-3], therapy, diagnostic timelines, and overall survival (OS) were captured.</div></div><div><h3>Results</h3><div>A total of 159 provisional CUP patients (<em>n</em> = 54 intervention cohort, <em>n</em> = 105 control cohort) were included. WGS and WTS were successfully carried out in 46 (85%) and 27 patients (50%). A primary tumor diagnosis was established in 76% of the intervention cohort compared with 16% of the control cohort (<em>P</em> &lt; 0.001). WGS contributed to a primary tumor diagnosis in 34 patients (63%) and identified an actionable alteration in 34 patients (63%). WTS contributed to a primary tumor diagnosis in three patients (6%). Following WGS, treatment recommendations could be made for 38 patients (70%), of whom 22 started the recommended therapies (58%). The median OS was 11 and 9 months in the intervention and control cohorts, respectively (<em>P</em> = 0.345).</div></div><div><h3>Conclusion</h3><div>Incorporation of WGS into the CUP care pathway is of significant value for diagnosing a primary tumor of origin and contributed to the identification of actionable alterations in the majority of patients.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 5","pages":"Article 105069"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143921678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter re: The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial","authors":"Arif Hakan Önder","doi":"10.1016/j.esmoop.2025.105066","DOIUrl":"10.1016/j.esmoop.2025.105066","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 5","pages":"Article 105066"},"PeriodicalIF":7.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143890584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}